The predominant mode of death for most patients with soft tissue sarcomas (STS) remains distant metastasis (DM). Current clinical predictors of DM are unreliable. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) correlate with biologic aggression in other tumors. The gene expression of the gelatinase, MMP-2 and MMP-9, and their respective inhibitors, TIMP-1 and TIMP-2, in STS was evaluated. Twelve fresh-frozen surgical specimens from patients with large (>5 cm) STS were analyzed. Six patients developed DM while 6 survived disease-free (DFS) at a minimum follow-up of 13 months. Following mRNA isolation, reverse transcription-polymerase chain reaction was performed using primers for MMP-2, MMP-9, TIMP-1, and TIMP-2. Gene expression was determined by band densitometry. Ratios of MMP-9/TIMP-1 and MMP-2/ TIMP-2 gene expression as well as MMP-2 protein activation ratio (active/inactive enzyme determined by gelatin zymography) were analyzed for correlation with DM and DFS. MMP-2 gene was expressed in 12 specimens, while MMP-9 was detectable in 9. Relative levels of MMP-2 and MMP-9, MMP2/TIMP-2 ratio, and MMP-9/TIMP-1 ratio were not significantly correlated with DM. Poor DFS was significantly correlated with high MMP-9/TIMP-1 ratio (p = 0.02). Active MMP-2 protein was detected in 12 specimens, while active MMP-9 protein was detected in 2. No association was found between MMP-2 protein activation ratio and DM or DFS. While MMP-2 gene expression and protein activity occurred in these 12 specimens, gelatinase/inhibitor ratios (for both MMP-2 and MMP-9) appear to be poor predictors of DM in STS.

Lindberg RD, Martin RG, Romsdahl MM, et al: Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas. Cancer 1981;47:2391–2397.
Suit HD, Mankin HJ, Wood WC, et al: Treatment of the patient with stage M0 soft tissue sarcoma. J Clin Oncol 1988;6:854–862.
Scully SP, Oleson JR, Leopold KA, et al: Clinical outcome after neoadjuvant thermoradiotherapy in high grade soft tissue sarcomas. J Surg Oncol 1994;57:143–151.
Pisters PW, Leung DH, Woodruff J, et al: Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996;14:1679–1689.
Tierney JF, Mosseri V, Stewart LA, Souhami RL, Parmar MK: Adjuvant chemotherapy for soft-tissue sarcoma: Review and meta-analysis of the published results of randomised clinical trials. Br J Cancer 1995;72:469–475.
Yamamoto H, Itoh F, Adachi Y, et al: Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepatocellular carcinoma. Gastroenterology 1997;112:1290–1296.
Koshiba T, Hosotani R, Wada M, et al: Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic cancer. Cancer 1998;82:642–650.
Sugiura Y, Shimada H, Seeger R, et al: Matrix metalloproteinase-2 and -9 are expressed in human neuroblastoma: Contribution of stromal cells to their production and correlation with metastasis. Cancer Res 1998;58:2209–2216.
Nuovo GJ, MacConnell PB, Simsir A, et al: Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical cancer. Cancer Res 1995;55:267–275.
Alessandro R, Minafra S, Pucci-Minafra I, et al: Metalloproteinase and TIMP expression by the human breast cell line 8701-BC. Int J Cancer 1993;55:250–255.
Ray JM, Stetler-Stevenson WG: The role of matrix metalloproteinases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J 1994;7:2062–2072.
Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260–1270.
Moses MA, Sudhalter J, Langer R: Identification of an inhibitor of neovascularization from cartilage. Science 1990;248:1408–1410.
Sipos EP, Tamargo RF, Weingart JD, Brem H: Inhibition of tumor angiogenesis. Ann NY Acad Sci 1994;732:263–272.
Taraboletti G, Garofalo A, Belotti D, et al: Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995;87:293–298.
Brown PD, Giavazzi R: Matrix metalloproteinase inhibition: A review of anti-tumour activity. Ann Oncol 1995;6:967–974.
Liotta LA, Tryggvason K, Garbisa S, et al: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284:67–68.
MacDougall JR, Matrisian LM: Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion, and metastasis. Cancer Metastasis Rev 1995;14:351–362.
Schultz RM, Silberman S, Persky B, et al: Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res 1988;48:5539–5545.
Matrisian LM, Hogan BL: Growth factor-regulated proteases and extracellular matrix remodeling during mammalian development. Curr Top Dev Biol 1990;24:219–259.
Matrisian LM: The matrix-degrading metalloproteinases. Bioessays 1992;14:455–463.
Albini A, Melchiori A, Santi L, et al: Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 1991;83:775–779.
DeClerck YA, Perez N, Shimada H, et al: Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992;52:701–708.
Khokha R, Zimmer MJ, Wilson SM, Chambers AF: Up-regulation of TIMP-1 expression in B16-F10 melanoma cells suppresses their metastatic ability in chick embryo. Clin Exp Metastasis 1992;10:365–370.
Soini Y, Salo T, Oikarinen A, et al: Expression of 72 kilodalton and 92 kilodalton type IV collagenase in malignant fibrous histiocytomas and dermatofibromas. Lab Invest 1993;69:305–311.
Koop S, MacDonald IC, Luzzi K, et al: Fate of melanoma cells entering the microcirculation: Over 80% survive and extravasate. Cancer Res 1995;55:2520–2523.
Chambers AF, MacDonald IC, Schmidt EE, et al: Steps in tumor metastasis: New concepts from intravital videomicroscopy. Cancer Metastasis Rev 1995;14:279–301.
Berend KR, Toth AP, Harrelson JM, et al: Association between the ratio of matrix metalloproteinase-1 to tissue inhibitor of matrix metalloproteinase-1 and local recurrence, metastasis, and survival in human chondrosarcoma. J Bone Joint Surg 1998;80:11–17.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.